Innovating Works

FASTer

Financiado
Identifying the Fast-acting Antidepressant Signatures of Treatment Response with...
Identifying the Fast-acting Antidepressant Signatures of Treatment Response with psychedelic compounds using a novel behavioral tracking system and single-cell resolution Mental health disorders affect 84 million people across Europe and are associated with an economic burden of €600 billion/year. New evidence from clinical trials suggests that a single treatment with psychedelic compounds, such as... Mental health disorders affect 84 million people across Europe and are associated with an economic burden of €600 billion/year. New evidence from clinical trials suggests that a single treatment with psychedelic compounds, such as psilocybin, can produce a fast (hours) and sustained (months) antidepressant (AD) response. However, many questions still remain about its mechanism of action, due to methodological challenges such as lack of knowledge of the brain cells and circuits where AD effects are taking place and limitations of the behavioral tests used to examine AD activity in rodents. Combining molecular, behavioral and advanced computational tools, FASTer will establish a groundbreaking and automatic behavioral tracking system to deconstruct the behavioral language associated with treatment response. In addition, FASTer will identify the brain cells and circuits responsible for the fast-acting and sustained AD effects of psilocybin. This is a move away from the traditional assessment of single behavioral readouts to unconventional group behaviors and endophenotypes in a translationally-relevant context that will cause a paradigm shift and revolutionize the field of behavioral phenotyping. Thanks to my unique know-how in bridging human and pre-clinical psychiatry, and to go beyond the state-of-the-art, I will combine activity-dependent labelling techniques and single-cell methods to identify the genes and brain circuits engaged during psilocybin treatment. To address the multidimensional nature of psychiatric disorders, I will manipulate gene networks related to the AD effects of psilocybin. The ambitious and innovative studies proposed here have the potential to change our understanding of psychiatric disorders, and transform the field of behavioral neuroscience. Ultimately, FASTer holds tremendous promise for translatability of preclinical findings and impacting the development of fast-acting and efficacious treatments for psychiatric disorders. ver más
31/12/2028
KI
2M€
Duración del proyecto: 61 meses Fecha Inicio: 2023-11-17
Fecha Fin: 2028-12-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-11-17
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-2023-STG: ERC STARTING GRANTS
Cerrada hace 2 años
Presupuesto El presupuesto total del proyecto asciende a 2M€
Líder del proyecto
KAROLINSKA INSTITUTET No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5